CYP19A1 and polycystic ovary syndrome: 1. IUA rat model: Improved endometrial thickness and glands; Decreased fibrotic area; Increased pregnant rate and the number of implanted embryos; Decreased conception time.2. POI mice model: Increased the number of primordial primary secondary and antral follicles; Increased the level of E2 and AMH; Decreased FSH level; Improved proliferation rate and Inhibited apoptosis of GCs; Increased number of FSHR+/AMH+ GCs and FOXL2+CYP19A1+ GCs.3. In vitro model: Promoted cell growth and inhibited apoptosis of CCs from PCOS patients.